FDA Approvals of 2012

16 of 39


Drug: Kyprolis
Generic molecule: carfilzomib
Company: Onyx Pharmaceuticals
Approval date: July 20

The scoop: Kyprolis is for the treatment of multiple myeloma patients who have already failed two therapies, making it a last-ditch option for many. It won accelerated approval from the FDA. And analysts think the drug, which comes with a price of about $10,000 a month, could generate upward of $1.5 billion a year in sales. Its approval also has sparked talk of a buyout of developer Onyx ($ONXX) with Bayer seen as a likely bidder.